ImmunityBio (IBRX) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for ImmunityBio (IBRX) over the last 5 years, with Sep 2025 value amounting to -$0.07.
- ImmunityBio's EPS (Weighted Average and Diluted) rose 50.00% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.41, marking a year-over-year increase of 55.43%. This contributed to the annual value of -$0.62 for FY2024, which is 46.09% up from last year.
- As of Q3 2025, ImmunityBio's EPS (Weighted Average and Diluted) stood at -$0.07, which was up 30.00% from -$0.10 recorded in Q2 2025.
- In the past 5 years, ImmunityBio's EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q3 2025 and a low of -$0.38 during Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.19, with a median of -$0.19 in 2023.
- In the last 5 years, ImmunityBio's EPS (Weighted Average and Diluted) tumbled by 40.74% in 2023 and then soared by 76.32% in 2024.
- Quarterly analysis of 5 years shows ImmunityBio's EPS (Weighted Average and Diluted) stood at -$0.23 in 2021, then declined by 17.39% to -$0.27 in 2022, then slumped by 40.74% to -$0.38 in 2023, then soared by 76.32% to -$0.09 in 2024, then skyrocketed by 50.00% to -$0.07 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.07 for Q3 2025, versus -$0.10 for Q2 2025 and -$0.15 for Q1 2025.